"Chiltern has already established a strong presence in this region with its offices in India, Singapore and Australia and, hence, forming a legal entity in other important countries in the region is a natural progression to enhance our global reach," said Dr. Umakanta Sahoo, Chiltern’s executive director, Asia Pacific, and managing director, India. "With the regional collaboration between Asian countries for mutual acceptance of Asian data, Japan, USA and European clients have shown increased interest in Taiwan to perform global clinical trials due to supportive regulatory environment, excellent hospital infrastructure and healthcare system."
